Our study demonstrated, for the first time, that genes related to cholesterol metabolism, including Cyp7a1, may participate in NAFLD progression through Mettl3-mediated m6A modification. Here, CYP7A1 is linked to metabolic dysfunction-associated steatotic liver disease.